Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial

Warner Postma, Enrico Fabris, Martin van der Ent, Rik Hermanides, Pawel Buszman, Clemens von Birgelen, Stéphane Cook, Hans Wedel, Giuseppe De Luca, Ronak Delewi, Felix Zijlstra, Elvin Kedhi*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).

Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited.

Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).

Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.

Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

Original languageEnglish
Number of pages6
JournalCatheterization and cardiovascular interventions
DOIs
Publication statusE-pub ahead of print/First online - 3 Jul 2019

Fingerprint

Stents
Thrombosis
Myocardial Infarction
Safety
zotarolimus
ST Elevation Myocardial Infarction
Stroke
Hemorrhage
Myocardial Revascularization
Drug-Eluting Stents
Percutaneous Coronary Intervention
Cause of Death
Mortality

Keywords

  • Acute myocardial infarction
  • Antiplatelet therapy
  • Coronary artery disease
  • Drug-eluting stents (DES)
  • Stent thrombosis

Cite this

Postma, Warner ; Fabris, Enrico ; van der Ent, Martin ; Hermanides, Rik ; Buszman, Pawel ; von Birgelen, Clemens ; Cook, Stéphane ; Wedel, Hans ; De Luca, Giuseppe ; Delewi, Ronak ; Zijlstra, Felix ; Kedhi, Elvin. / Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI) : A prespecified prospective register from the DAPT-STEMI trial. In: Catheterization and cardiovascular interventions. 2019.
@article{a689414cc33b4f63bbe0143c1f4d6102,
title = "Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial",
abstract = "Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2{\%}) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8{\%}), 9 (0.8{\%}), 34 (3.4{\%}), 2 (0.2{\%}), and 4 (0.4{\%}). The rate of target lesion revascularizations involving the culprit lesion was 1.1{\%}. Target lesion failure was 1.5{\%}. The rate of definite ST was 0.5{\%}. The rate of both definite or probable ST was 0.7{\%}.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.",
keywords = "Acute myocardial infarction, Antiplatelet therapy, Coronary artery disease, Drug-eluting stents (DES), Stent thrombosis",
author = "Warner Postma and Enrico Fabris and {van der Ent}, Martin and Rik Hermanides and Pawel Buszman and {von Birgelen}, Clemens and St{\'e}phane Cook and Hans Wedel and {De Luca}, Giuseppe and Ronak Delewi and Felix Zijlstra and Elvin Kedhi",
year = "2019",
month = "7",
day = "3",
doi = "10.1002/ccd.28376",
language = "English",
journal = "Catheterization and cardiovascular interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI) : A prespecified prospective register from the DAPT-STEMI trial. / Postma, Warner; Fabris, Enrico; van der Ent, Martin; Hermanides, Rik; Buszman, Pawel; von Birgelen, Clemens; Cook, Stéphane; Wedel, Hans; De Luca, Giuseppe; Delewi, Ronak; Zijlstra, Felix; Kedhi, Elvin.

In: Catheterization and cardiovascular interventions, 03.07.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI)

T2 - A prespecified prospective register from the DAPT-STEMI trial

AU - Postma, Warner

AU - Fabris, Enrico

AU - van der Ent, Martin

AU - Hermanides, Rik

AU - Buszman, Pawel

AU - von Birgelen, Clemens

AU - Cook, Stéphane

AU - Wedel, Hans

AU - De Luca, Giuseppe

AU - Delewi, Ronak

AU - Zijlstra, Felix

AU - Kedhi, Elvin

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

AB - Objectives: To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second-generation Resolute™ zotarolimus-eluting stent (R-ZES) in patients enrolled in the DAPT-STEMI Trial (NCT01459627).Background: R-ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited. Methods: The Resolute-STEMI is a prespecified prospective register that reports the safety and efficacy of R-ZES in setting of ST-Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all-cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R-ZES. At 6 months the PE occurred in 42 (4.2%) patients. All-cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short-term and mid-term clinical outcomes with the R-ZES stent in setting of STEMI. At 30 days and 6-months R-ZES has an outstanding safety and efficacy even in this high-risk category of patients.

KW - Acute myocardial infarction

KW - Antiplatelet therapy

KW - Coronary artery disease

KW - Drug-eluting stents (DES)

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85068619480&partnerID=8YFLogxK

U2 - 10.1002/ccd.28376

DO - 10.1002/ccd.28376

M3 - Article

AN - SCOPUS:85068619480

JO - Catheterization and cardiovascular interventions

JF - Catheterization and cardiovascular interventions

SN - 1522-1946

ER -